Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$13.9 million.

  • Northwest Biotherapeutics' Cash from Operations fell 6874.77% to -$13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.2 million, marking a year-over-year increase of 671.82%. This contributed to the annual value of -$57.0 million for FY2024, which is 630.16% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Cash from Operations stood at -$13.9 million, which was down 6874.77% from -$6.7 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Cash from Operations ranged from a high of -$6.7 million in Q2 2025 and a low of -$20.2 million during Q4 2024
  • Its 5-year average for Cash from Operations is -$12.2 million, with a median of -$12.4 million in 2024.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Cash from Operations tumbled by 12983.03% in 2022, and later soared by 5870.84% in 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Cash from Operations (Quarter) stood at -$11.2 million in 2021, then grew by 21.31% to -$8.8 million in 2022, then tumbled by 91.64% to -$17.0 million in 2023, then dropped by 19.01% to -$20.2 million in 2024, then skyrocketed by 31.16% to -$13.9 million in 2025.
  • Its last three reported values are -$13.9 million in Q3 2025, -$6.7 million for Q2 2025, and -$9.4 million during Q1 2025.